Future Applications of Electronic-Nose Technologies in Healthcare and Biomedicine by Alphus Dan Wilson
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
15 
Future Applications of Electronic-Nose 
Technologies in Healthcare and Biomedicine 
Alphus Dan Wilson 
USDA Forest Service, Southern Hardwoods Laboratory 
United States of America 
1. Introduction 
The development and utilization of many new electronic-nose (e-nose) applications in the 
healthcare and biomedical fields have continued to rapidly accelerate over the past 20 years. 
Innovative e-nose technologies are providing unique solutions to a diversity of complex 
problems in biomedicine that are now coming to fruition. A wide range of electronic-nose 
instrument types, based on different operating principles and mechanisms, has facilitated 
the creation of different types and categories of medical applications that take advantage of 
the unique strengths and advantages of specific sensor types and sensor arrays of different 
individual instruments. Electronic-nose applications have been developed for a wide range 
of healthcare sectors including diagnostics, immunology, pathology, patient recovery, 
pharmacology, physical therapy, physiology, preventative medicine, remote healthcare, and 
wound and graft healing. E-nose biomedical applications range from biochemical testing, 
blood compatibility, disease diagnoses, drug purity, monitoring metabolic levels, organ 
dysfunction, and telemedicine. This review summarizes some of the key technological 
developments of electronic-nose technologies, arising from past and recent biomedical 
research, and identifies a variety of future e-nose applications currently under development 
which have great potential to advance the effectiveness and efficiency of biomedical 
treatments and healthcare services for many years. A concise synthesis of the major 
electronic-nose technologies developed for healthcare and medical applications since the 
1980s is provided along with a detailed assessment and analysis of future potential 
advances in electronic aroma detection (EAD) technologies that will provide effective 
solutions to newly-emerging problems in the healthcare industry. These new e-nose 
solutions will provide greatly improved quality controls for healthcare decisions and 
diagnoses as well as badly needed final confirmations of appropriate patient treatments. The 
purpose of this chapter is to provide some detailed insights into current and future e-nose 
applications that will yield a variety of new solutions to detection-related tasks and difficult 
problems in the fields of healthcare and biomedicine. The uses of electronic-noses for quality 
control (QC) and quality assurance (QA) issues, associated with numerous diagnostic-
testing activities conducted within the medical field, also are discussed. 
2. History of Electronic-nose developments for biomedical applications 
Use of the olfactory sense (of smell) as an indicator of disease probably originated with 
Hippocrates around 400 BC. Observations that unusual human odors or aromas provided 
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some indication of human ailments caused early medical practitioners to recognize that the 
presence of human diseases changed the odor of bodily excretions that could be used to 
diagnose certain common diseases. 
2.1 Early use of aroma-detection in evaluating health conditions 
Medical doctors have utilized the sense of smell to facilitate determinations of the physical 
state and general health of their patients for centuries. The application of smell as useful 
sensory clues used by physicians to identify the causes of human ailments resulted in the 
development of qualitatively descriptive odors (or aromas) and specialized terms used to 
describe and identify odors associated with specific human diseases and physiological 
disorders. Some descriptive aromas found to be associated with some common human 
diseases are presented in Table 1. The use of olfactory information provided valuable 
additional information for physicians in assessing patient conditions and formulating 
accurate diagnoses before modern analytical equipment and chemical-detection devices 
became available for this purpose. Notice that in some cases the same term, such as “amine-
like” for bacterial vaginosis and bladder infections, occasionally was used to describe common  
 
Disease / Disorder Body source Descriptive aroma References 
Anaerobic infection Skin, sweat Rotten apples Pavlou & Turner, 2000 
Bacterial vaginosis Vaginal fluid Amine-like Pavlou & Turner, 2000 
Bladder infection Urine Amine-like Pavlou & Turner, 2000 
Congestive heart 
failure 
Heart Dimethyl sulfide Smith, 1982 
Fetor hepaticus Breath Newly-mown clover Hayden, 1980 
Gout Skin Gouty odor Liddell, 1976 
Hyperaminoaciduria Infant skin Dried malt or hops Liddell, 1976 
Hypermethioninemia Infant breath Sweet, fruity, fishy Liddell, 1976; Hayden, 
1980 
Isovaleric acidemia Skin, breath Sweaty, cheesy Hayden, 1980; Pavlou 
& Turner, 2000 
Ketoacidosis Breath Acetone-like Hayden, 1980 
Liver failure Breath Musty fish, feculent Hayden, 1980; Smith, 
1982  
Maple syrup disease Sweat, urine Maple syrup Liddell, 1976; Pavlou 
& Turner, 2000 
Pseudomonas infection Skin, sweat Grape Pavlou & Turner, 2000 
Scrofula Body Stale beer Liddell, 1976 
Smallpox Skin Pox stench Liddell, 1976 
Trimethylaminuria Skin, urine Fishy Pavlou & Turner, 2000 
Typhoid Skin Freshly-baked bread Liddell, 1976; Hayden, 
1980 
Uremia Breath Fishy, ammonia Hayden, 1980 
Yellow fever Skin Butcher’s shop Liddell, 1976; Hayden, 
1980 
Table 1. Descriptive aromas previously used for diagnosing human diseases 
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odors associated with completely different diseases. This occurred because different 
diseases can result in the production of very similar compounds even though the 
mechanism of disease is quite different. In other cases such as for use of the term “fishy” for 
hypermethioninemia and uremia, both of these diseases cause the buildup of similar or 
identical compounds in the blood due to similar physiological processes that are often 
referred to as in-born genetic or metabolic diseases resulting from the absence of certain 
enzymes or the failure of certain organs. Many other metabolic diseases caused by genetic 
enzyme deficiencies are associated with various distinctive odors due to the accumulation of 
undecomposed metabolites in the body. 
Some descriptive aromas, such as maple syrup and pox stench, are so diagnostic that the 
aroma was named after the specific disease referred to by name. Other diagnostic terms for 
descriptive aromas include fetor hepaticus, diabetic breath, and uremic breath which have 
been included in common medical vocabulary and continue to be used to some extent even 
in contemporary vernacular. Once modern analytical instrumentation became available in 
the twentieth century, the actual volatile compounds responsible for these characteristic 
smells began to be identified. Probably the first such identification was done by Linus 
Pauling, the noted chemist who was able to freeze out and identify some of the volatiles in 
urine using cold traps, followed by gas chromatography (Pauling et al., 1971). Many other 
discoveries of VOCs associated with specific human smells related to particular diseases 
followed in subsequent years leading up to the identification of diagnostic bioindicators of 
disease. These compounds are highly correlated with the presence of specific diseases in the 
body as discussed in the following section. 
2.2 Discovery of bioindicators of disease 
The discovery and recognition of particular volatile organic compounds (VOCs), released 
from various diseased human body parts or fluids derived from these tissues, have been 
found to be associated with specific human diseases through the use of specialized modern 
analytical instruments. These instruments have included such analytical machines as gas 
chromatographs working in tandem with mass spectrometers (GC-MS) and other such 
technical instruments used in analytical chemistry. The results of intense chemical analyses 
from numerous research studies have been the identification of many volatile biomarkers of 
disease and their associated chemical structures. The identification of unique molecular 
markers (volatile metabolites) associated with particular diseases has become an extremely 
effective and powerful tool for the early detection of diseased tissues and infectious agents 
in the human body. For example, the analysis of patients’ breath odors has had a long 
history of application for the detection of various human diseases, not only respiratory 
diseases. Even though the human breath contains hundreds of volatile organic compounds 
at low concentrations, relatively few (less than fifty) of these are detected in the majority of 
healthy humans under normal physiological conditions (Phillips et al., 1999a). However, a 
much smaller number of aberrant VOCs are often found only in patients when disease is 
present somewhere in their bodies. Thus, the association of specific volatile metabolites, 
released within the expired human breath of patients, not only provides indicators of 
particular diseases, but also reflect the overall physiological state as an indication of general 
health and a useful index of disease (Jacoby, 2004). These volatile markers of disease often 
are released several hours to several days before outwardly-noticeable physical symptoms 
of illness appear and thus provide early indicators of disease or physiological disorders. 
New molecular markers that are indicators of specific diseases, both infectious and 
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noninfectious, are being increasingly revealed by new scientific research. Some examples of 
these volatile molecular biomarkers (or bioindicators) of disease and physiological 
disorders, reported hitherto by various researchers, are summarized in Table 2. 
 
Disease / Disorder Volatile chemical biomarkers References 
Allograft rejection Carbonyl sulfide Studer et al., 2001 
Breast cancer C4-C20 alkanes Phillips et al., 2003b 
Cholera p-menth-1-en-8-ol, dimethyl 
disulphide 
Garner et al., 2009 
Chronic hepatitis Methyl-mercaptan, dimethyl sulfide Kaji et al., 1978 
Cirrhosis Dimethyl sulfide, mercaptans Chen et al., 1970 
Cystic fibrosis Leukotriene B4, interleukin-6, 
carbonyl sulfide, alkanes 
Carpagnano et al., 2003; 
Phillips et al., 2004 
Diabetes Acetone, ethanol, methyl nitrate Rooth & Ostenson, 1966; 
Crofford et al., 1997; 
Ping et al. 1997; Novak 
et al., 2007 
Halitosis Methanethiol, Hydrogen sulfide, 
methyl mercaptan, dimethyl sulfide 
Kaizu, 1976; Van den 
Velde et al., 2009 
Hepatic encephalopathy 3-methylbutanal Goldberg, 1981 
Histidinemia 2-imidazolepyruvic acid,  
2-imidazolelactic acid,  
2-imidazoleacetic acid 
Bondy & Rosenberg, 
1980 
Liver cancer Hexanal, 1-octen-3-ol, octane Xue et al., 2008 
Lung cancer Alkanes, ketones, specific aromatic 
hydrocarbons (benzene derivatives) 
Manolis, 1983; Gordon 
et al., 1985; Preti et al., 
1988; Phillips et al., 
1999b, 2003a 
Maple syrup disease 2-oxoisocaproic acid Bondy & Rosenberg, 
1980 
Necrotizing enterocolitis 2-Ethyl-1-hexanol De Lacy Costello et al., 
2008 
Oxidative stress 8-isoprostane Montuschi et al., 1999 
Periodontal disease Pyridine, picolines Kostelc et al., 1981 
Phenylketonuria Phenylpyruvic acid, phenyllactic 
acid, phenylacetic acid 
Bondy & Rosenberg, 
1980 
Schizophrenia Pentane, carbon disulfide Smith & Sines, 1960; 
Smith et al., 1969; 
Phillips et al., 1993 
Tyrosinemia p-hydroxyphenylpyruvic acid Bondy & Rosenberg, 
1980 
Trimethylaminuria Trimethylamine Pavlou & Turner, 2000 
Uremia Dimethylamine, trimethylamine Simenhoff et al., 1977 
Table 2. Molecular biomarker VOCs of specific human diseases and disorders 
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Analysis of expired human breath is considered particularly valuable because it can be 
monitored noninvasively (without causing physical damage to patients), yet provide 
information about the chemical and physiological state of the entire body. The reason that 
information about the physical health of the entire body is possible by the analysis of 
expired breath is because most volatile metabolites of infectious agents of disease, or those 
produced from abnormal tissues, are eventually eliminated from the body through the 
lungs, often soon after being formed within diseased tissues. Alternatively, other less 
volatile abnormal metabolites are eliminated through the urine which may be similarly 
analyzed using aroma-sensing instruments such as electronic noses. 
Cao and Duan (2006) summarized some of the advantages and disadvantages of breath 
analysis for clinical practice and diagnosis. They found breath tests were noninvasive, easily 
repeated, and caused less discomfort and embarrassment to patients than blood and urine 
tests. Breath samples closely reflected arterial concentrations and provided much less 
complicated mixtures than serum or urine analyses and more direct information on 
respiratory function than by other means. They listed limitations of breath testing for clinical 
practice to include the lack of standardization of analytical methods, the high water content 
of breath samples affecting detection, relatively expensive costs compared to simple 
chemical tests (but much less time-consuming for results), and the lack of well-established 
links between breath VOCs and certain kinds of diseases. Biomarkers in chronic obstructive 
pulmonary disease (COPD) also may be useful in aiding diagnosis, monitoring exacerbations, 
evaluating effects of drugs, and defining specific phenotypes of disease (Borrill et al., 2008). 
Frey & Suki (2008) found risk assessments, disease progression, and control of asthma and 
COPD required multidimensional fluctuation analysis of the dynamics of lung-function 
parameters that needed to be quantified and monitoring via precise biomarkers of these 
diseases using instruments capable of direct, electronic monitoring of these biomarkers. 
The importance of the use of biomarkers for the detection of disease has become so 
prominent that Bentham Science, a leading international publisher of high quality scientific 
journals, decided to launch a new journal called Recent Patents on Biomarkers in January 2011 
to publish reviews and research articles written by experts on recent patents and research 
relating to biomarkers in basic and applied, medical, environmental, and pharmaceutical 
research, and including patent biomarker applications, clinical development, and molecular 
diagnostics. 
3. Current e-nose technologies utilized in healthcare and biomedicine 
Electronic-noses are ideal instruments for biomedical uses because of their versatility, low-
cost, rapid output of results, capabilities of continuous operation (for physiological- 
monitoring purposes), and the wide range of VOCs and other cellular chemical constituents 
that may be analyzed. The potential for miniaturization of electronic-nose devices also is 
great due to their microcircuitry and microsensor components. Some key ways in which e-
noses have been particularly useful in various sectors of the healthcare industry are 
discussed in the following sections. 
3.1 Electronic-nose technology types and applications 
A variety of different types of e-noses, based on different working principles, have been 
used for biomedical tasks including conductive polymers (CP), metal-oxide semiconductor 
(MOS), quartz crystal microbalance (QCM), and surface acoustic waves (SAW) among 
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others. Each e-nose technology has different advantages, disadvantages, and limitations that 
largely determine what types of medical applications that individual e-nose sensor types are 
best suited for in practical clinical settings. 
3.2 Point-of-care medicine 
Point-of-care testing (POCT) may be defined as diagnostic testing at or near the site of 
patient care (Kost, 2002). The objective of POCT is to bring the test conveniently and 
immediately to the patient. The POCT approach to diagnostic testing increases the 
likelihood that the patient will receive the results and treatment in a timely manner. POCT is 
accomplished through the use of transportable, portable, and handheld instruments and test 
kits. The use of cheaper, smaller, faster, and smarter POCT devices, such as e-noses, has 
increased the use of POCT approaches by making diagnostic tests more cost-effective for 
many diseases. 
3.3 Working e-nose applications in current medical practice 
E-noses in general have the advantages of providing patient laboratory results much faster 
than standard cultures or wet chemistry tests and the capability of providing early 
detections of diseases before symptoms appear. These characteristics have been compelling 
reasons for the development of e-nose systems for clinical medicine. Some recent uses of 
electronic noses in hospitals and universities around the world are presented in Table 3. 
The development of new e-nose applications for POC treatments will no doubt continue to 
increase as the breadth of existing e-nose systems is expanded with new capabilities and 
practical e-nose uses are discovered and implemented through more extensive empirical 
testing. This work will require extensive trials in hospitals and clinics as well as in the field 
(for portable units) to determine the range of multiple tasks that individual e-nose systems 
can perform for various types of detection and diagnostic testing needs. The cooperation of 
many levels of healthcare professions working in cooperation with e-nose manufacturers, 
clinical technicians and medical research scientists will be required to accomplish these 
tasks. This effort is quite a challenge in many situations because of the limited time available 
to physicians for testing new experimental equipment. 
3.3.1 Health monitoring 
Continuous monitoring of the physiological states of patients is essential to determine the 
current physiological condition of patients and whether treatment and recovery is 
progressing favorably. For example, the continuous monitoring of serum glucose levels, 
particularly with the aid of sophisticated algorithms, provides a means of generating alerts 
when glucose concentration exceeds the normal high and low threshold ranges (Sparacino et 
al., 2010). Monitoring exhaled VOC biomarkers of endogenous metabolic processes using 
electronic noses is an ideal means of detecting altered metabolic pathways resulting from 
diseases such as diabetes. The use of e-nose sensors for continuous glucose monitoring 
requires accurate calibration, filtering of data to enhance the signal-to-noise ratio, and 
effective predictions of future glucose concentration in order to generate alerts with minimal 
risk of causing false alarms or missing entirely the occurrence of life-risking events. 
Electronic-nose devices also might be used to facilitate the study of transcriptional gene 
regulation of glucose sensors in pancreatic β-cells and liver by monitoring changes in breath 
volatiles (primarily ethanol, acetone, and methyl nitrate) associated with hyperglycemia in 
type 2 diabetes patients (Bae et al., 2010; Lee et al., 2009). 
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Country 
Hospital, University 
or Research Facility 
E-nose 
utilized 
Application References 
USA University of 
Pennsylvania 
Experimental 
model 
Distinguish 
cerebrospinal 
fluid 
Thaler et al., 
2000 
USA Merck Research 
Laboratories 
Fox 4000 Flavor 
analysis for 
drug 
formulation 
Zhu et al.,  
2004 
United 
Kingdom 
Birmingham 
Heartlands Hospital 
Cyranose 320 Identify 
Staphalococcus 
Dutta et al., 
2005 
Germany University of 
Applied Sciences 
DE 101 Detect renal 
dysfunction 
Voss et al., 
2005 
USA Cleveland Clinic unspecified Diagnose lung 
cancer 
Erzurum et al., 
2005 
Belgium University of 
Antwerp 
PEN 2 Clinical 
diagnoses of 
bacteria 
Moens et al., 
2006 
United 
Kingdom 
South Manchester 
University Hospital 
experimental 
model 
Burn and 
wound 
infection 
types 
Persaud,  
2006 
USA University of 
Pennsylvania 
unspecified Diagnosis of 
diseases via 
breath 
Anthes,  
2008 
USA California Institute 
of Technology 
JPL ENose Detect & 
differentiate 
brain cancers 
Kateb et al., 
2009 
Australia Prince Charles 
Hospital 
unspecified Detect chronic 
lung disease 
Dent,  
2010 
Netherlands Amsterdam 
Academic Medical 
Center 
Cyranose 320 Discriminate 
inflammation 
airway 
diseases 
Lazar et al., 
2010 
Italy Catholic University experimental 
model 
Asthma 
detection 
Montuschi, 
2010 
Tanzania National Institute of 
Medical Research 
Bloodhound 
EN 
Diagnosis of 
Tuberculosis 
Kolk et al., 
2010 
United 
Kingdom 
Gloucestershire 
Royal Hospital 
NST 3320 Diagnosis of 
ventilator-
associated 
pneumonia 
Humphreys  
et al., 2011 
 
Table 3. Electronic-nose uses in hospitals and universities around the world 
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Monitoring inorganic anions and cations in the body are equally important for maintaining 
proper electrolyte levels and water balance in tissues. Thus, routine clinical assays of 
electrolyte levels (such as chloride, sodium, and potassium) in biological samples like 
serum, blood, plasma, and urine provide useful information about the proper functioning of 
organ systems and regulatory hormones of patients receiving treatments. Assessing urinary 
chloride concentration helps in the diagnostic evaluation of metabolic alkalosis and other 
physiological conditions caused by improper osmotic pressure, water imbalances within 
extracellular spaces, and acid-base imbalance. The Microcontroller P89C668 is an instrument 
that measures urinary chloride concentration to determine body electrolyte levels based on a 
mercuric thiocyanate colorimetric principle (Vasumathi & Neelamegam, 2010). This 
instrument works by measuring color intensity of a colored complex formed between 
chloride ions and mercuric thiocyanate which is proportional to the chloride concentration 
in the sample. Colorimetric e-noses operate similarly by measuring changes in absorbance 
caused by color changes resulting from interactions of the target analyte with an organic 
dye. 
3.3.2 Infection and disease detection 
Electronic-nose systems probably were first tested for disease detection in the biomedical 
field through the discrimination of pathogenic microbes in pure cultures (Gardner et al., 
1998). Microbial identification is an integral part of infectious disease diagnosis and the 
subsequent determination of proper treatments as a consequence of the wide range of 
disease mechanisms associated with pathogenesis generated by various microbial agents. 
Dutta et al. (2002) used a portable Cyranose 320 e-nose, consisting of 32 polymer carbon 
black composite sensors, to identify six bacterial species responsible for eye infections. The 
bacteria were cultured at various concentrations in a saline solution and the VOCs from the 
headspace were analyzed using linear PCA and other data-clustering algorithms. The Self 
Organizing Map (SOM) network provided an accuracy of 96% for bacterial classification, 
but the Radial basis function network (RBF) allowed identifications with up to 98% 
accuracy. Most laboratory-grade instruments such as the Cyranose 320 are now being 
replaced with simpler and cheaper e-noses that are easier to use by trained clinical 
technicians. Many new types of experimental e-noses, based on different operating 
principles, currently are being tested for numerous healthcare applications. 
Microbial biosensors are being employed increasingly to detect human diseases. These 
sensors, like e-noses, consist of a transducer that converts biochemical signals into a 
quantifiable electronic response, but instead of utilizing electronic sensors, the transducer is 
used in conjunction with either viable or unviable microbial cells. A variety of different 
transducers may be used such as acoustic, electrochemical, electric, or optical types. D’Souza 
(2001) did an early review of applications of microbial biosensors and gave some 
advantages and limitations of various types. Biosensors will be discussed in greater detail in 
section 4.2.1. 
3.3.3 Detecting exposure to toxins and hazardous chemicals 
Food safety and exposure to toxic substances in the environment has become of greater 
concern to man in the world today as a result of the acceleration and increasing frequency of 
bioterrorism and the growing susceptibility of world crops to toxic sprays and disease due 
to the planting of crop monocultures and the application of agricultural chemicals from the 
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air. Toxic volatile solvents also are found in the air within certain areas of hospitals despite 
the filtering of air. All of these opportunities for incidental human exposures to toxic 
substances necessitate the monitoring of food supplies and ambient air to assure that levels 
of harmful substances are below damaging levels. The occurrence of various toxins in food 
is potentially very harmful to human health. Sensor technologies such as electronic noses 
have been recognized as possible useful tools for determinations of the geographical origin 
of food products, now quite important for the identification of food lots that have become 
contaminated by toxins or other harmful substances in order to remove these specific food 
sources from grocery shelves (Luykx & van Ruth, 2008). Other examples include the 
occurrence of mycotoxins, toxic secondary metabolites (e.g. aflatoxin and ochratoxin A) 
produced by fungi such as Aspergillus and Fusarium species that commonly grow on 
agricultural products in the field or in storage (Huang et al., 2006). Cheli et al. (2009) very 
effectively utilized the PEN2 e-nose with principal component analysis (PCA) to detect the 
presence of aflatoxin in maize samples at a high level of confidence. This method was 
potentially useful for screening maize food lots for aflatoxin contamination prior to 
marketing. 
Mujahid et al. (2010) used cholesteric liquid crystals (CLCs) as sensitive coatings on acoustic 
devices such as QCM e-noses for the detection of organic solvent vapors of both polar and 
non-polar compounds by the frequency shift of analyte samples. They were able to gain 
mechanical stability by combining CLCs with imprinted polymers. This e-nose application 
would be useful for detection of pharmaceutical preparations requiring solvent extraction or 
delivery, and for detection of potential patient exposures to hazardous chemical solvents in 
the hospital environment. 
3.4 Quality control 
There are many potential uses for e-nose instruments in quality control (QC) applications in 
medicine. These machines can be used to quickly double check diagnoses to help assure that 
patients are receiving the correct and precise treatments prescribed by physicians. Another 
possible related application is the e-nose evaluation of food quality and control measures to 
assure that food contaminants and toxins, that can adversely affect food safety and human 
health, are not present. Improved QC has been accomplished through use of specialized 
algorithms that increase analyte discriminations and confirm the results. 
3.4.1 Electronic-nose algorithms 
The efficiency with which electronic-nose systems are able to identify and discriminate 
VOCs associated with analyte mixtures largely depends on the effectiveness of 
discriminating algorithms used during headspace analysis. Pattern-recognition algorithms 
are heavily used for integrating signal outputs of sensor arrays and comparing such outputs 
to patterns of known analyte standards held in recognition reference libraries. This 
discrimination process is very similar to those used in GC-MS analyses that use reference 
libraries. New gas-recognition algorithms have provided a means of improving the 
effectiveness, robustness, and accuracy of gas detection and identification for the medical 
industry. 
Flitti et al. (2008) developed a gas-recognition algorithm for an on-chip Complementary 
Metal-Oxide Semiconductor (CMOS) tin-oxide (SnO2) gas sensor array that operates at high 
temperature (typically 300°C) with the advantages of cost effectiveness and high sensitivity 
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to various gases, but the disadvantages of low selectivity, high sensitivity to humidity, 
nonlinearities of sensor-response, and drift in signal output. Many pattern-recognition 
algorithms have attempted to correct for low selectivity of sensors, yet most do not address 
the problem of drift which was largely corrected according to experimental results in this 
study, indicating that more than 98% correct recognition was obtained using this robust 
method. Polat and Güneş (2006) proposed a decision-tree classifier system using fuzzy 
weighted preprocessing methods for the diagnosis of erythemato-squamous diseases. They 
used twelve clinical-evaluation criteria and twenty-two histopathological features in the 
diagnostic analysis. Similar fuzzy-reasoning methods have been used in e-nose algorithms 
to discriminate sensor-array patterns produced from headspace volatiles. Thus, many 
different types of diagnostic information may be used in these decision-tree classifiers. 
Seising (2006) created a similar model using fuzzy reasoning to address the phenomenon of 
vagueness in a physician’s style of thinking concerning reasoning used to make clinical 
diagnoses. 
3.4.2 Drug development, purity, and delivery 
Spin-offs of electronic-nose technologies similar to conductive polymer (CP) e-noses, but 
with single sensors instead of an array, are being developed to work in aqueous solutions 
for the detection of drugs and other chemicals used in pharmaceutical preparations. 
Manganese (III) porphyrins are particularly useful for the construction of polymeric 
membranes. Vlascici et al. (2010) developed ion-selective electrode sensors composed of two 
types of manganese (III) porphorins, high molecular weight polyvinyl chloride (PVC) and 
sol-gel, for the determination of diclofenac in pharmaceutical preparations by direct 
potentiometry. Diclofenac is a nonsteroidal drug used in the treatment of ankylosing 
spondylitis, osteoarthritis, and rheumatoid arthritis due to its antipyretic, anti-inflammatory 
and analgesic properties. Their best results were obtained with PVC membrane plasticized 
with dioctylphtalate and incorporated with sodium tetraphenylborate as a lipophilic anionic 
additive. Electrode response to diclofenac was linear in the concentration range of 3 × 10-6 to 
1 × 10-2 M and in good agreement with a High Pressure Liquid Chromagraphy (HPLC) 
reference method. 
Continuous glucose monitoring systems (CGM) may soon offer the possibility of continuous 
dynamic assessment and control of daily fluctuations in blood glucose concentration for 
diabetes treatment. The emergence of a new generation of open-loop and closed-loop 
subcutaneous insulin-infusion devices that are controlled by continuous glucose-monitoring 
sensors will soon make glycemic control and insulin treatment more reliable (Torres et al., 
2010). New smart machines are on the horizon to simplify diurnal treatments, allowing 
diabetics to be less attentive to their daily insulin needs. 
4. Future potential medical applications of electronic noses 
The potential applications of electronic-nose devices in the healthcare and biomedical 
industries will continue to expand with greater research and in-hospital testing as new ways 
of using these chemical-detection machines are discovered, and the breadth of capabilities 
widened, particularly in the area of coordinated uses in combination with other medical 
devices. The combined uses of e-noses with other electronic medical instruments will 
facilitate the development and availability of improved real-time information of patient 
conditions, leading to even more effective decisions and treatments by physicians in 
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hospitals and POCT clinics. The future potential of combining the capabilities of e-nose 
devices with other types of detection technologies are examined here in light of new 
technological discoveries in chemical sensor-detection that are currently emerging. 
4.1 Emerging e-nose biomedical developments 
Electronic noses have even greater potential synergistic capabilities when used 
cooperatively in combination with many other electronic medical devices. The potential 
advantages of combining their use are enormous considering the possible permutations of 
combinations in which these analytical devices may be combined for cooperative tasks. 
Sometimes these advantages are so useful that e-noses are often combined with other 
technologies to produce compound e-nose instruments. Both theoretical and practical 
aspects of these conceptual instrument mergers are discussed in greater detail in section 4.3. 
4.2 E-nose uses in cooperative combination with other electronic devices 
Synergistic applications of e-nose technologies, used in combination with other medical 
devices, are receiving increasing attention in the healthcare industry because these 
instrument-combinations are viewed as ways of achieving greater cooperative effectiveness 
in improving clinical services to patients. Complimentary information obtained in this way 
leads to better diagnoses and prognoses. The ultimate results of synergistic uses of 
instrument combinations are better, more detailed and quality information for medical 
decisions and thus more effective treatments leading to faster patient recoveries. 
One key area where electronic noses are effectively used in combination with other medical 
instruments is in the application of e-nose information on various physiological conditions 
of patients toward more effective treatments for particular ailments. E-nose information 
may be used to confirm the physiological states or functions in patients that are identified in 
pre-scanning and preliminary assessments of patient conditions during initial examinations. 
Medical infrared thermography (MIT) is a non-invasive, non-radiating thermal imaging 
method used to analyze physiological functions based on localized thermal abnormalities 
characterized by increases or decreases in skin temperature. MIT involves detection of 
infrared radiation usually related to variations in blood flow that affect skin temperature. 
Reduced muscular activity or degeneration leads to dermal hyperthermia whereas 
inflammation causes a hyperthermic pattern. Use of a MIT detection tool has been 
particularly useful in sports medicine for pre-screening athletes for injuries or muscular 
inflammation and degeneration (Hildebrandt et al., 2010). E-noses also might be used in 
combination with wearable motion-sensing sensor technologies for confirming physiological 
activities after monitoring mobility-related activities in individuals with chronic disease 
conditions (Allet et al., 2010). Electronic-noses could be used in combination with drug-
delivery devices to monitor physiological responses and provide feedback to these devices 
during or following the administration of drugs. The feedback would then adjust the rate of 
drug-delivery to ease physiological stress of adverse reactions and thus regulate release 
rates of drug payloads and resorption rates (Anglin et al., 2008). Similar systems are possible 
using fiber-optic sensors such as the Sencil system for continuous monitoring of glucose 
(Liao et al., 2010). Other potential applications include uses in combination with associated 
cerebrospinal fluid (CSF) tests for analysis and monitoring of specific CSF constituents 
associated with specific diseases (Di Terlizzi & Platt, 2009), and in combination with the 
Liver Disease Quality of Life (LDQOL) instrument for liver transplantation evaluation in 
ambulatory adults with advance, chronic lung disease (Gralnek, 2000). 
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4.2.1 Biosensors 
Biosensors are analytical devices that combine a biological-sensing element with a chemical 
or physical transducer to quantitatively and selectively detect the presence of specific 
compounds in a given external environment (Vo-Dinh and Cullum, 2000). Chaubey and 
Malhotra (2002) summarized the commercialization and applications of four different types 
of mediated biosensors based on the type of transducer used to convert the physico-
chemical change in the selected biologically-active material, resulting from interactions with 
the analyte to produce the output signal. Biosensor technologies previously have been 
divided into optical, calorimetric, piezoelectric, and electrochemical biosensors. Optical 
sensors as based on the measurement of light absorbed or emitted from a biochemical 
reaction and guided with optical fibers into the sensor. Calorimetric biosensors detect the 
analyte by the heat released from the biochemical reaction of the analyte with a suitable 
enzyme. Piezoelectric biosensors operate by generating electrical dipoles through the 
subjection of anisotropic natural crystals to mechanical stress. The adsorption of an analyte 
to the sensing crystal increases the mass of the crystal which alters its frequency of 
oscillation that is recorded in the instrument output. QMB e-nose sensors essentially operate 
by this same principle. Electrochemical (EC) biosensors measure the generation or 
consumption of electrons during a bio-interaction process. EC biosensors are the most 
commonly used class of biosensors and are further subdivided into amperometric, 
conductometric, and potentiometric sensor types depending on the electrochemical property 
to be measured by the detector system. Specific EC biosensors such as the Ion selective 
electrodes (ISE), ion selective field effect transistors (ISFET), and pH electrodes usually 
measure the oxidation of specific substrates to produce an oxidized product. Two mediated 
biosensors were previously commercialized early on in biosensor development, including 
the lactate analyzer (LA 640) in 1976 and a glucose analyzer in 1987. The LAPS (light 
addressable potentiometric sensor) optical biosensor was commercialized in 1993. 
New types of biosensor technologies have been tested and developed recently. For example, 
Thanyani et al. (2008) examined an affinity biosensor technology to detect antibodies to 
mycolic acid in tuberculosis patients. Mycolic acids are useful detection targets for 
tuberculosis because each Mycobacterium species produces unique types of mycolic acids in 
chemical structure and in association with specific liposomes. Komaitis et al. (2010) 
developed a fully-automated flow-injection bioluminescent biosensor for the assessment of 
water toxicity, particularly heavy metal toxicity. Kumar & Kumar (2008) analyzed a DNA 
biosensor for selective detection of target genes responsible for diseases using DNA 
hybridization with a specific probe. PCR-free DNA biochips are emerging new tools in the 
field of diagnosis because of the greater advantages of electrochemical biosensors due to the 
electrochemical behavior of labels associated with hybridization. 
There are several notable recent reviews on the development of biosensor applications 
within the biomedical field. Yoo & Lee (2010) recently reviewed the present status and use 
of glucose biosensors in the management of diabetes in clinical practice. Dzyadevych et al. 
(2008) discussed the advantages and disadvantages of amperometric enzyme biosensors for 
medical diagnostics and other potential healthcare applications. Gomila et al. (2006) 
described some advances in the development of methods and techniques for the production, 
mobilization, electrical characterization, and development of olfactory nanobiosensors. 
Implantable short-term and long-term biosensors offer utility for a plethora of clinical 
applications, particularly in the areas of point-of-care medicine, intensive care, and surgery 
(Guiseppi-Elie, 2010). Biosensors provide invaluable real-time data on the metabolic and 
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physiological status of patients that are required by clinicians and physicians to make 
medically-important, informed decisions that impact the short- and long-term outcome of 
patients. These devices potentially could save countless lives in the emergency room or in 
triage on the battle field where patient mortality is high due to trama-induced 
hemorrhaging and rapid decisions concerning patient status are essential to provide 
immediate care to individuals based on their current condition. 
4.2.2 BioMEMS and MIP sensors 
Biological Micro-Electro-Mechanical Systems (BioMEMS), also known as BioChips, are 
micro- or nano-scale devices that detect biochemical entities by either mechanical, electrical, 
or optical means. Mechanical BioMEMS use cantilever sensors on a chip that operate in 
either stress-sensing or mass-sensing mode. In stress-mode sensing, biochemical reactions 
cause changes in surface free energy resulting in stress and bending of the cantilever. In 
mass-mode sensing, the cantilever is excited mechanically so that it vibrates as a certain 
resonant frequency. A change in mass due to adsorption of chemical species on the sensor is 
detected by shifts in the resonant frequency. BioMEMS have a wide variety of important 
biomedical applications including the processing, delivery, manipulation, analysis, and 
construction of biological and chemical entities (Bashir, 2004). Some important major areas 
of research and applications range from diagnostic detections (e.g. DNA and protein micro-
assays), micro-fluidics, and tissue engineering to surface modification, drug preparation and 
delivery, cell lysing, mixing, separation, implantable monitoring and sensing. Diagnostics 
probably represents the largest segment of applications because a very large number of 
BioMEM devices have been developed for diagnostic applications. Diagnostic detections of 
pathogenic viruses, bacteria, and fungi as well as small molecular components produced by 
these microbes may be detected. The advantages of using micro- and nano-scale detection 
technologies are greater portability through miniaturization, higher sensitivity, reduced 
reagent volumes with lower associated costs, and perhaps most useful is reduced time to 
results due to smaller volumes and higher effective concentrations (Bashir, 2004). Aponte et 
al. (2006) summarized the potential uses of BioMEMS devises to detect the presence of 
molecular markers in body fluids as indicators of immune system responses. The reviewed 
research focused on candidate biomarkers that could be useful for in-flight monitoring of 
astronaut immune status using MEMS and Nano-Electro-Mechanical System (NEMS) 
devices. They found cytokine levels were significantly affected by space flight conditions. 
Cytokines are chemical messengers directly related to immune responses and various 
diseases. They are classified as chemokines, colony-stimulating factors, growth factors, 
interleukins, interferons, lymphokines, stress proteins, and tumor necrosis factors 
(Stvrtinova et al., 1995). 
Molecular Imprinted Polymer (MIP) microsensors utilize polymeric materials for the 
recognition of particular chemical substances that are complementary to a specific receptor 
cavity. MIP materials usually consist of a copolymerized monomer matrix cross-linked to a 
template molecule that creates a receptor cavity complimentary to the template molecule 
when the template is removed from the polymer matrix (Tokonami et al., 2009). These 
nanostructured MIP objects may be used to develop micro-and nano-sized sensors or sensor 
arrays for chemical sensing and detection. The small size of MIP materials provides the 
advantages of faster equilibrium with the analyte, increased number of accessible 
complementary cavities per material weight, and enhanced catalytic activity of the sensor 
surface. Large-scale sensor array systems utilizing MIP sensors are capable of handling large 
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sample throughput as high density detection for primarily biochemically-related substances 
such as enzymes, antibodies, and DNA (Tokonami et al., 2009). 
4.2.3 Electroconductive hydrogels 
Electroconductive hydrogels (ECH) are composite biomaterials made of polymeric blends 
that combine conductive electroactive polymers (CEPs) with highly hydrated hydrogels. 
They bring together the redox-switching and electrical properties of conductive electroactive 
polymers (CEPs) with the small-molecule transport and compatibility of cross-linked 
hyrogels (Guiseppi-Elie, 2010). CEPs are incorporated into biosensors for the detection of 
chemical species (e.g., antigens, drug metabolites, enzyme substrates, neurotransmitters, 
and ssDNA fragments) of medical importance. Biosensors based on CEPs operate either 
with electrochemical, gravimetric, or optical detectors. They are used for measurements of 
constituents in low-volume samples with continuous-flow systems and fast response times, 
high sensitivities, and detection limits in the μM range for enzyme substrates, and even 
lower detection ranges for DNA fragments. CEPs do have some serious limitations 
including slow switching speeds in bio-electronic applications, formation of reactive species 
due to over-oxidation, and time-temperature drift. ECH-based sensors are a new class of 
devices with potential for in vivo biocompatibility in human-implantable biosensors, low 
voltage actuation for electrically-stimulated drug release devices, and with low interfacial 
impedances suitable for neural prosthetic devices such as deep-brain stimulation electrodes 
(Guiseppi-Elie, 2010). ECH characteristics of soft elastic nature, low interfacial tension, and 
high swelling capacity results in low tissue irrigation and high permeability to low 
molecular weight drugs and metabolites (Li et al., 2004). These characteristics have allowed 
hydrogels to be used in biosensors, catheters, contact lenses, wound dressings, and 
tourniquets. Hydrogels can be designed to possess hydration characteristics and mechanical 
properties similar to that of human tissue. Thus, uses of ECH as a biorecognition membrane 
layer in biosensors has extended potential applications to clinically important biomedical 
diagnoses (using analyte-specific enzymes), neural prosthetic and recording devices (NDPs 
and NRDs), electro-stimulated drug-release devices (ESDRDs) and implantable 
electrochemical biosensors. A hydrogel synthesized from a poly(HEMA)-based hydrogel 
and poly(aniline was fashioned into a biosensor (by incorporation into recombinant 
cytochrome P450-2D6) that was responsive to the drug fluoxetine, the active ingredient in 
Prozac (Iwuoha et al., 2004). These polymeric materials provide a non-cytotoxic interface 
between the biosensor device and native living tissue or cell culture medium (Fonner et al., 
2008). 
Gawel et al. (2010) reviewed the various principles involved in the design of biospecific 
hydrogels acting through various molecular mechanisms to transduce the recognition of 
label-free analytes. The range of different responsive characteristics displayed by hydrogels 
include changes in equilibrium swelling volume in response to various changes in solution 
parameters such as solvent pH, ionic strength, temperature, electrical fields, and presence of 
surfactants. 
4.2.4 Porous polymers and resins 
Porous polymers and resins provide applications as enantio-selective catalysts, artificial 
antibodies, and sensors in electro-optical and micro-electronic devices. Unlike inorganic 
porous gels such as silica gel carriers, porous polymers have unique properties such as 
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flexibility, ductility, and capability to incorporate a wide range of organic functional groups 
useful for biotechnical and biomedical sensor applications (Hentze & Antonietti, 2002). 
Initial applications of porous polymers have included uses as insulators and ion exchange 
resins, employed in the field of column chromatography for separation and purification of 
organic compounds. Applications of porous polymers have now been extended into sensor 
development. Some potential pharmaceutical applications of template porous polymer gels 
are in the development of controlled drug-delivery devices, drug-monitoring devices, and 
for biological receptor mimetics. These materials have become particularly useful as active 
components in optical sensors. 
4.3 Compound electronic-nose devices 
E-nose hybrid devices are created by combining e-nose technologies with other types of 
sensors into one instrument. This is different from instrument systems such as GC-MS or 
HPLC-MS instruments used in tandem. In an e-nose hybrid device, different sensor types 
are found within the same instrument not in separate instruments combined in tandem. 
There are a number of different combined-technology commercial e-noses available with 
various types of e-nose sensors combined with other sensor types. The e-nose components 
of such compound-sensor devices usually contain MOS, SAW, QMB, or CB electronic-nose 
sensors with different combinations of electron capture (EC), ion mobility spectrometer 
(IMS), photoionization (PI), mass spectrometer (MS), oxygen (O2), carbon dioxide (CO2), and 
humidity sensors. The sensing range and capabilities of these compound e-noses are 
considerably greater, but also generally more expensive than typical e-nose devices alone. 
The efficacy and justification of expense depends on the particular combination of sensing 
needs that are required for specific medical applications. 
Other possibilities exist for integrating e-nose components with DNA probes within a 
microarray. One such possibility might be the integration of the CombiMatrix microarray 
system with 12,544 electrodes in which multiplexed CMOS microarray DNA probes are on 
individual electrodes coated with electro-polymerized polypyrrole (PPY) that is a common 
material used in many conductive polymers e-noses (Maurer et al., 2010). The possibility of 
combining PPY sensors for detecting DNA as well as other similar sensors for VOCs within 
the same instrument is theoretically possible. Lorenzelli et al. (2005) have integrated a MOS 
detector with a microcapillary GC silicon-based system for clinical diagnostics and other 
biomedical applications. Initial planned future work are to test this biosensor-based e-nose 
micro-GC system for determining and monitoring hamovanillic acid (HVA) and 
vanillylmandelic acid (VMA) catecholamine metabolite concentrations, end-products of 
dopamine and norepinephrine metabolism, in urine samples as well as for oncological 
(cancer) diagnoses. 
5. Conclusions 
Many research and development (R&D) feasibility studies have demonstrated the 
effectiveness of electronic-nose technologies for detection-type applications in many diverse 
areas of the healthcare and biomedical industries. Electronic noses have proven to be very 
competent and effective in discriminating between VOCs and other cellular biochemical 
constituents, showing great potential for improving and speeding up detections for a 
myriad of applications. Most of this feasibility work has been done with expensive 
laboratory-grade instruments designed to allow maximum discriminations and sample-
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sensitivity for rigorous scientific testing. Consequently, a number of major problems have 
resulted from attempts by commercial e-noses manufacturers to use laboratory-grade 
instruments for practical clinical POCT applications. Laboratory-grade instruments 
generally are too expensive, too complicated for operation by industry technicians, require 
extensive training (for operation, maintenance, and data-interpretation), and are too 
versatile in terms of numbers and permutations of control settings that are possible 
(adjustable) which complicates repeatability (precision and accuracy) within the normal 
range needed for diagnostic testing. All of these problems have contributed to the failure of 
applying laboratory-grade e-nose instruments to practical applications. The common 
mistake and practice of skipping the additional needed steps of customizing e-noses (in both 
design and operation) for specific biomedical applications has been costly, causing some 
potential end-users to lose faith in e-nose technologies, and has resulted in the business 
failures of some e-nose instrument manufacturers as a result of marketing instruments that 
are not simplified, adapted, and customized to the specific uses required by healthcare 
professionals. 
Now, the electronic-nose industry is at the stage where lessons of design and manufacture 
have been learned and the path forward has shifted to designing e-noses that are smaller, 
less expensive, more application-specific (specialized), easier to use by operators, and 
produce results that are easily interpreted by the user due to limited data outputs. The only 
final steps left to be completed today for e-nose development for practical uses in many 
modern-day applications are largely limited to efficacy testing to determine such things as 
the range and breadth of applications of individual instruments, procedural uses that are 
possible in combination with other medical instruments or diagnostic tests, quality control 
between individual instruments (calibration concerns), and developing specialized aroma 
libraries, software and algorithms for specific medical applications. Once these tasks are 
completed, use of electronic noses should accelerate in diagnostic laboratories and POCT 
clinics, replacing many conventional time-consuming methods and instruments used in 
diagnostics and providing fast, reliable information useful for speeding up effective patient 
care with the most appropriate treatments. 
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